Alnylam CSO receives stock award for 20-year service

ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported an equity award of company common stock.

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. chief scientific officer Kevin Joseph Fitzgerald reported an equity award of company common stock. He acquired 158 shares of common stock on February 23, 2026 at a stated price of $0.00 per share as a grant/award.

According to the footnotes, this grant reflects shares issued in recognition of 20 years of continuous employment under a program that provides stock with an aggregate value of $100,000 to each qualifying employee, net of minimum statutory tax withholding. After this award, his directly held common stock totals 21,422 shares.

The filing also reports 537 shares of common stock held indirectly in a managed account, reflecting shares acquired through the company’s 401(k) matching contribution program.

Insider Trade Summary

Grant/Award: 158 shares

Grant/Award 2 txns

Insider Fitzgerald Kevin Joseph

Role CSO & EVP, Head of Research

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	158	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 21,422 shares (Direct); Common Stock — 537 shares (Indirect, by Managed Account)

Footnotes (2)

1. F1. On February 23, 2026, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $100,000 to each employee who completes 20 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 20 years of continuous employment on December 5, 2025.
2. F2. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ALNY chief scientific officer Kevin Fitzgerald report on this Form 4?

Kevin Fitzgerald reported an acquisition of common stock through an equity award, not an open-market trade. He received 158 shares of Alnylam Pharmaceuticals common stock as a grant recognizing long-term service, increasing his directly held stake to 21,422 shares after the transaction.

How many Alnylam (ALNY) shares did Kevin Fitzgerald acquire in the reported grant?

He acquired 158 shares of Alnylam common stock in the reported award. The transaction was coded as a grant or other acquisition with a stated price of $0.00 per share, reflecting stock-based compensation rather than a purchase on the open market.

Why did Alnylam (ALNY) grant Kevin Fitzgerald additional shares of common stock?

The shares were granted to recognize 20 years of continuous employment with Alnylam. A company committee approved a program issuing common stock with an aggregate value of $100,000 to each employee who completes 20 consecutive years, with Fitzgerald’s award delivered net of minimum statutory tax withholding.

What indirect Alnylam (ALNY) share holdings does Kevin Fitzgerald report on this Form 4?

He reports 537 shares of Alnylam common stock held indirectly in a managed account. A footnote explains these shares were acquired under the company’s 401(k) plan through the employer matching contribution program, representing retirement-plan related holdings rather than discretionary stock purchases.

Does this Alnylam (ALNY) Form 4 show Kevin Fitzgerald buying or selling shares on the market?

The filing does not show market purchases or sales; it records an equity award. The primary transaction is a grant-coded acquisition of 158 shares at $0.00 per share, reflecting stock compensation, plus updated reporting of indirectly held 401(k) plan shares.

How significant is Kevin Fitzgerald’s reported Alnylam (ALNY) stock grant for existing shareholders?

The grant is a routine employee service award and relatively small in size. It adds 158 directly held shares and updates 537 indirect 401(k) shares, representing ordinary compensation-related issuance rather than a large insider sale or substantial change in ownership structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Kevin Joseph

(Last) (First) (Middle)

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CSO & EVP, Head of Research

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		A(1)		158	A	$0.0	21,422	D
Common Stock								537	I	by Managed Account(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On February 23, 2026, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $100,000 to each employee who completes 20 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 20 years of continuous employment on December 5, 2025.

2. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

	By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.